Skip to main content
Accueil
  • fr
  • en

Main navigation

  • Company
    • Company profile
    • Management
      • Leadership Team
      • Board of Directors
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • Publications
  • Products
    • Pipeline overview
    • ------------------
    • Lacutamab
    • IPH4502
    • Monalizumab
    • Other Clinical Stage Assets
      • IPH6501
      • IPH6101
      • IPH6401
      • IPH5201
      • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers
Menu

Leadership Team

  1. Home
  2. Company
  3. Management

Jonathan DICKINSON, MBA, BSc

Chief Executive Officer

Yannis MOREL, PhD

Executive Vice President, Chief Operating Officer

Markus Jensen, MD

Vice President, Chief Medical Officer

Odile BELZUNCE

Vice President Compliance & Operations, Interim Human Resources Head

Stéphanie CORNEN

Vice President, Investor Relations, Communication & Commercial Strategy

Claire de SAINT BLANQUAT

Vice President, Legal and Corporate Affairs

FRÉDÉRIC LOMBARD, MBA

Senior Vice President, Chief Financial Officer

Related links

Board of Directors

Footer

  • Contact
  • Location
  • Site map
  • Legal Info
  • Terms of use
  • Privacy Notice
  • Cookies notice
  • General Conditions of Purchase

Follow us

   

Stay in touch

 Subscribe to our newsletter

 Contact us
 

Location

117, Avenue de Luminy - BP 30191
13 009 Marseille FRANCE

+33 (0)4 30 30 30 30

 

Innate Pharma
  • Company
    • Company profile
    • Management
      • Leadership Team
      • Board of Directors
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • Publications
  • Products
    • Pipeline overview
    • ------------------
    • Lacutamab
    • IPH4502
    • Monalizumab
    • Other Clinical Stage Assets
      • IPH6501
      • IPH6101
      • IPH6401
      • IPH5201
      • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers